Fairvalue-Calculator Fairvalue-Calculator
EN DE

AnnJi Pharmaceutical Co (7754) Fair Value & Analysis

Healthcare · TW · Market cap 5.9B TWD

Price60.00 TWD
Fair Value9.53 TWD
Upside-84.1%
Quality95/100
Evidence: Low Range 7.14 TWD – 11.91 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

AnnJi Pharmaceutical Co (7754) currently trades at 60.00 TWD, while our model-based Fair Value estimate is 9.53 TWD — implying the stock looks roughly 84.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is AnnJi Pharmaceutical Co (7754) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 9.53 TWD versus a price of 60.00 TWD — about −84% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 7754?
Our 21-model fair value for AnnJi Pharmaceutical Co is 9.53 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 60.00 TWD.
What is the quality score of 7754?
AnnJi Pharmaceutical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.